Takeda Pharmaceutical Company (TAK) Revenue & Revenue Breakdown
Takeda Pharmaceutical Company Revenue Highlights
Latest Revenue (Y)
$4.26T
Latest Revenue (Q)
$1.05T
Main Segment (Y)
Gastroenterology
Main Geography (Y)
UNITED STATES
Takeda Pharmaceutical Company Revenue by Period
Takeda Pharmaceutical Company Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $4.26T | 5.87% |
| 2023-03-31 | $4.03T | 12.85% |
| 2022-03-31 | $3.57T | 11.61% |
| 2021-03-31 | $3.20T | -2.84% |
| 2020-03-31 | $3.29T | 56.93% |
| 2019-03-31 | $2.10T | 18.45% |
| 2018-03-31 | $1.77T | 2.22% |
| 2017-03-31 | $1.73T | -4.17% |
| 2016-03-31 | $1.81T | 1.66% |
| 2015-03-31 | $1.78T | 5.09% |
| 2014-03-31 | $1.69T | 8.63% |
| 2013-03-31 | $1.56T | 3.20% |
| 2012-03-31 | $1.51T | 6.31% |
| 2011-03-31 | $1.42T | -3.18% |
| 2010-03-31 | $1.47T | -4.70% |
| 2009-03-31 | $1.54T | 11.90% |
| 2008-03-31 | $1.37T | 5.34% |
| 2007-03-31 | $1.31T | 7.67% |
| 2006-03-31 | $1.21T | 7.95% |
| 2005-03-31 | $1.12T | 3.36% |
| 2004-03-31 | $1.09T | 3.86% |
| 2003-03-31 | $1.05T | 4.08% |
| 2002-03-31 | $1.01T | 4.32% |
| 2001-03-31 | $963.48B | 4.37% |
| 2000-03-31 | $923.13B | - |
Takeda Pharmaceutical Company generated $4.26T in revenue during NA 2024, up 5.87% compared to the previous quarter, and up 203.31% compared to the same period a year ago.
Takeda Pharmaceutical Company Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.05T | -5.43% |
| 2023-12-31 | $1.11T | 6.53% |
| 2023-09-30 | $1.04T | -1.47% |
| 2023-06-30 | $1.06T | 10.72% |
| 2023-03-31 | $956.16B | -12.80% |
| 2022-12-31 | $1.10T | 9.40% |
| 2022-09-30 | $1.00T | 3.07% |
| 2022-06-30 | $972.47B | 11.36% |
| 2022-03-31 | $873.29B | -3.11% |
| 2021-12-31 | $901.29B | 6.68% |
| 2021-09-30 | $844.82B | -11.03% |
| 2021-06-30 | $949.60B | 23.28% |
| 2021-03-31 | $770.27B | -7.94% |
| 2020-12-31 | $836.75B | 6.06% |
| 2020-09-30 | $788.93B | -1.61% |
| 2020-06-30 | $801.85B | 3.91% |
| 2020-03-31 | $771.70B | -10.20% |
| 2019-12-31 | $859.32B | 5.95% |
| 2019-09-30 | $811.05B | -4.48% |
| 2019-06-30 | $849.12B | 18.39% |
| 2019-03-31 | $717.21B | 43.61% |
| 2018-12-31 | $499.40B | 15.93% |
| 2018-09-30 | $430.78B | -4.24% |
| 2018-06-30 | $449.83B | 12.19% |
| 2018-03-31 | $400.96B | -17.86% |
| 2017-12-31 | $488.15B | 12.69% |
| 2017-09-30 | $433.18B | -3.36% |
| 2017-06-30 | $448.24B | 7.70% |
| 2017-03-31 | $416.20B | -10.50% |
| 2016-12-31 | $465.05B | 11.58% |
| 2016-09-30 | $416.80B | -3.97% |
| 2016-06-30 | $434.00B | 4.80% |
| 2016-03-31 | $414.12B | -15.35% |
| 2015-12-31 | $489.21B | 6.87% |
| 2015-09-30 | $457.75B | 2.57% |
| 2015-06-30 | $446.30B | 1.93% |
| 2015-03-31 | $437.84B | -10.40% |
| 2014-12-31 | $488.63B | 11.00% |
| 2014-09-30 | $440.20B | 7.07% |
| 2014-06-30 | $411.15B | 1.57% |
| 2014-03-31 | $404.81B | -11.77% |
| 2013-12-31 | $458.82B | 9.83% |
| 2013-09-30 | $417.74B | 1.81% |
| 2013-06-30 | $410.30B | 11.45% |
| 2013-03-31 | $368.16B | -8.46% |
| 2012-12-31 | $402.17B | 3.48% |
| 2012-09-30 | $388.64B | -2.42% |
| 2012-06-30 | $398.29B | 4.45% |
| 2012-03-31 | $381.32B | -10.30% |
| 2011-12-31 | $425.11B | 23.12% |
| 2011-09-30 | $345.28B | -3.34% |
| 2011-06-30 | $357.22B | 5.61% |
| 2011-03-31 | $338.25B | -7.86% |
| 2010-12-31 | $367.11B | 2.16% |
| 2010-09-30 | $359.33B | 1.31% |
| 2010-06-30 | $354.70B | 4.93% |
| 2010-03-31 | $338.02B | -9.25% |
| 2009-12-31 | $372.49B | -1.06% |
| 2009-09-30 | $376.48B | -0.66% |
| 2009-06-30 | $378.98B | 12.93% |
| 2009-03-31 | $335.58B | -15.18% |
| 2008-12-31 | $395.62B | -3.57% |
| 2008-09-30 | $410.26B | - |
Takeda Pharmaceutical Company generated $1.05T in revenue during Q4 2024, up -5.43% compared to the previous quarter, and up 95.83% compared to the same period a year ago.
Takeda Pharmaceutical Company Revenue Breakdown
Takeda Pharmaceutical Company Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| Adcetris | $109.42B | $83.94B | $69.19B | $59.43B | $52.67B |
| Adderall XR | $41.76B | $24.30B | - | - | - |
| Advate | $122.91B | $118.19B | $118.49B | $128.53B | $157.86B |
| Adynovate/Adynovi | $66.31B | $66.55B | $60.73B | - | - |
| Albumin | $133.99B | $121.45B | $90.03B | $57.58B | $67.22B |
| Alofisel | $3.51B | $2.73B | $1.84B | $784.00M | $373.00M |
| Alunbrig | $28.52B | $20.56B | $13.64B | $8.81B | $7.24B |
| Azilva-F | $33.64B | $72.90B | $76.30B | $82.20B | $76.75B |
| Dexilant | $45.28B | $69.37B | $50.76B | $55.57B | $62.80B |
| Elaprase | $91.56B | $85.32B | $73.12B | $68.79B | $67.92B |
| Entyvio | $800.92B | $702.74B | $521.78B | $429.28B | $347.20B |
| Feiba | $40.54B | $41.27B | $39.16B | - | - |
| Fosrenol | $13.53B | - | - | - | - |
| Gastroenterology | $1.22T | $1.09T | $875.68B | $777.80B | $697.90B |
| Gattex/Revestive | $119.25B | $93.08B | $75.75B | $64.56B | $61.81B |
| Iclusig | $54.71B | $47.21B | $34.86B | $34.19B | $31.82B |
| Immunoglobulin | $644.59B | $522.21B | $385.86B | $334.87B | $298.70B |
| Intuniv | $33.55B | - | - | - | - |
| Leuplin/Enantone | $107.35B | $111.31B | $106.46B | - | - |
| Neuroscience | $627.01B | $637.71B | $482.29B | $417.30B | $438.52B |
| Ninlaro | $87.36B | $92.69B | $91.20B | $87.40B | $77.56B |
| Oncology | $462.36B | $438.74B | $468.73B | $416.51B | $420.96B |
| Other Gastroenterology | $82.23B | $72.39B | $82.88B | $99.66B | $103.54B |
| Other PDT Immunology | $39.99B | $34.79B | $31.05B | $27.93B | $28.25B |
| Other Product | $368.91B | $454.60B | $624.15B | $574.07B | $704.76B |
| Other Product, Other | $321.74B | $364.97B | $515.16B | $402.43B | $538.30B |
| Other Rare Hematology | $47.30B | $46.37B | $53.01B | $45.31B | $66.20B |
| PDT Immunology | $818.57B | $678.44B | $506.95B | $420.39B | $394.17B |
| Pantoloc/Controloc | $46.49B | $45.52B | $40.27B | - | - |
| Rare Diseases | $770.70B | $723.44B | $591.75B | $634.89B | - |
| Rare Hematology | $305.30B | $304.72B | $283.69B | $289.80B | $334.24B |
| Recombinate | $12.05B | $12.76B | $12.30B | - | - |
| Replagal | $73.55B | $66.74B | $51.71B | $51.76B | $51.25B |
| Takhzyro | $178.68B | $151.80B | $103.24B | $86.72B | $68.27B |
| Trintellix | $104.80B | $100.08B | $82.31B | $68.87B | $70.67B |
| Velcade | $5.54B | $27.76B | $110.05B | $101.11B | $118.32B |
| Vpriv | $51.30B | $48.37B | $42.41B | $38.52B | $38.01B |
| Vyvanse/Elvanse | $423.22B | $459.29B | $327.05B | - | - |
| Lotriga | - | $16.73B | $32.69B | $31.77B | $31.75B |
| Other Oncology | - | - | $43.33B | $30.21B | $24.31B |
| Other Hereditary Angioedema | - | - | $23.65B | $25.79B | - |
| Natpara/Natpar | - | - | $5.35B | - | - |
| Other Neuroscience | - | - | $72.93B | $76.90B | $69.47B |
| Rare Metabolic | - | - | $172.59B | $162.62B | $170.82B |
| Takecab-F | - | - | $102.40B | $84.82B | $72.71B |
| Diabetes | - | - | $133.04B | - | - |
| Firazyr | - | - | $26.69B | $26.82B | $32.66B |
| Hereditary Angioedema | - | - | $153.59B | $139.33B | $129.82B |
| Vyvanse | - | - | - | $271.53B | $274.08B |
| RECOMBINATE | - | - | - | $13.39B | - |
| PANTOPRAZOLE | - | - | - | $43.12B | $49.46B |
| Nesina-F | - | - | - | $57.67B | $57.96B |
| Natpara | - | - | - | $3.55B | $13.63B |
| Leuprorelin | - | - | - | $95.36B | $109.05B |
| FEIBA | - | - | - | $44.49B | $51.51B |
| Adynovate | - | - | - | $58.07B | $58.67B |
| Cinryze | - | - | - | - | $24.35B |
| Kalbitor | - | - | - | - | $4.54B |
Takeda Pharmaceutical Company's latest annual revenue breakdown by segment (product or service), as of Mar 24: Gastroenterology (14.25%), PDT Immunology (9.59%), Entyvio (9.38%), Rare Diseases (9.03%), Immunoglobulin (7.55%), Neuroscience (7.35%), Oncology (5.42%), Vyvanse/Elvanse (4.96%), Other Product (4.32%), Other Product, Other (3.77%), Rare Hematology (3.58%), Takhzyro (2.09%), Albumin (1.57%), Advate (1.44%), Gattex/Revestive (1.40%), Adcetris (1.28%), Leuplin/Enantone (1.26%), Trintellix (1.23%), Elaprase (1.07%), Ninlaro (1.02%), Other Gastroenterology (0.96%), Replagal (0.86%), Adynovate/Adynovi (0.78%), Iclusig (0.64%), Vpriv (0.60%), Other Rare Hematology (0.55%), Pantoloc/Controloc (0.54%), Dexilant (0.53%), Adderall XR (0.49%), Feiba (0.48%), Other PDT Immunology (0.47%), Azilva-F (0.39%), Intuniv (0.39%), Alunbrig (0.33%), Fosrenol (0.16%), Recombinate (0.14%), Velcade (0.06%), and Alofisel (0.04%).
Takeda Pharmaceutical Company Revenue Breakdown by Country
Annual Revenue by Country
| Country | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| Asia, Excluding Japan | $261.22B | $225.01B | $196.96B | - | - |
| UNITED STATES | $2.20T | $2.10T | $1.71T | $1.57T | $1.60T |
| Other Countries Not Separately Reported | $117.91B | $95.18B | $68.94B | $68.52B | $71.26B |
| Latin America | $198.10B | $160.38B | $128.47B | $121.64B | $143.46B |
| JAPAN | $451.39B | $512.04B | $658.98B | $559.75B | $592.79B |
| Europe And Canada | $966.84B | $842.67B | $739.17B | $666.18B | $645.53B |
| Azilva-F | - | - | $76.30B | - | - |
| Alunbrig | - | - | $13.64B | - | - |
| Alofisel | - | - | $1.84B | - | - |
| Albumin | - | - | $90.03B | - | - |
| Adynovate/Adynovi | - | - | $60.73B | - | - |
| Advate | - | - | $118.49B | - | - |
| Adcetris | - | - | $69.19B | - | - |
| Lotriga | - | - | $32.69B | - | - |
| Immunoglobulin | - | - | $385.86B | - | - |
| Iclusig | - | - | $34.86B | - | - |
| Hereditary Angioedema | - | - | $153.59B | - | - |
| Gattex/Revestive | - | - | $75.75B | - | - |
| Gastroenterology | - | - | $875.68B | - | - |
| Firazyr | - | - | $26.69B | - | - |
| Feiba | - | - | $39.16B | - | - |
| Entyvio | - | - | $521.78B | - | - |
| Elaprase | - | - | $73.12B | - | - |
| Diabetes | - | - | $133.04B | - | - |
| Dexilant | - | - | $50.76B | - | - |
| Velcade | - | - | $110.05B | - | - |
| Trintellix | - | - | $82.31B | - | - |
| Takhzyro | - | - | $103.24B | - | - |
| Takecab-F | - | - | $102.40B | - | - |
| Other Oncology | - | - | $43.33B | - | - |
| Other Neuroscience | - | - | $72.93B | - | - |
| Other Hereditary Angioedema | - | - | $23.65B | - | - |
| Other Gastroenterology | - | - | $82.88B | - | - |
| Oncology | - | - | $468.73B | - | - |
| Ninlaro | - | - | $91.20B | - | - |
| Neuroscience | - | - | $482.29B | - | - |
| Natpara/Natpar | - | - | $5.35B | - | - |
| Leuplin/Enantone | - | - | $106.46B | - | - |
| Vyvanse/Elvanse | - | - | $327.05B | - | - |
| Vpriv | - | - | $42.41B | - | - |
| Replagal | - | - | $51.71B | - | - |
| Recombinate | - | - | $12.30B | - | - |
| Rare Metabolic | - | - | $172.59B | - | - |
| Rare Hematology | - | - | $283.69B | - | - |
| Pantoloc/Controloc | - | - | $40.27B | - | - |
| PDT Immunology | - | - | $506.95B | - | - |
| Other Rare Hematology | - | - | $53.01B | - | - |
| Other Product, Other | - | - | $515.16B | - | - |
| Other Product | - | - | $624.15B | - | - |
| Other PDT Immunology | - | - | $31.05B | - | - |
| Asia | - | - | - | $156.24B | $165.40B |
Takeda Pharmaceutical Company's latest annual revenue breakdown by geography, as of Mar 24: UNITED STATES (52.39%), Europe And Canada (23.07%), JAPAN (10.77%), Asia, Excluding Japan (6.23%), Latin America (4.73%), and Other Countries Not Separately Reported (2.81%).
Takeda Pharmaceutical Company Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company | $4.26T | $1.05T |
| TEVA | Teva Pharmaceutical Industries | $15.85B | $4.16B |
| VTRS | Viatris | $15.43B | $3.66B |
| HLN | Haleon | $11.30B | $2.92B |
| BHC | Bausch Health Companies | $8.76B | $2.40B |
| ZTS | Zoetis | $8.54B | $2.36B |
| ELAN | Elanco Animal Health | $4.42B | $1.21B |
| CTLT | Catalent | $4.38B | $1.07B |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| EBS | Emergent BioSolutions | $1.05B | $254.70M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| EVO | Evotec SE | $781.43M | $208.73M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SIGA | SIGA | $139.92M | $21.81M |
| ESPR | Esperion Therapeutics | $116.33M | $73.83M |
TAK Revenue FAQ
What is Takeda Pharmaceutical Company’s yearly revenue?
Takeda Pharmaceutical Company's yearly revenue for 2024 was $4.26T, representing an increase of 5.87% compared to 2023. The company's yearly revenue for 2023 was $4.03T, representing an increase of 12.85% compared to 2022. TAK's yearly revenue for 2022 was $3.57T, representing an increase of 11.61% compared to 2021.
What is Takeda Pharmaceutical Company’s quarterly revenue?
Takeda Pharmaceutical Company's quarterly revenue for Q4 2024 was $1.05T, a -5.43% decrease from the previous quarter (Q3 2024), and a 9.91% increase year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $1.11T, a 6.53% increase from the previous quarter (Q2 2024), and a 1.33% increase year-over-year (Q3 2023). TAK's quarterly revenue for Q2 2024 was $1.04T, a -1.47% decrease from the previous quarter (Q1 2024), and a 4.07% increase year-over-year (Q2 2023).
What is Takeda Pharmaceutical Company’s revenue growth rate?
Takeda Pharmaceutical Company's revenue growth rate for the last 3 years (2022-2024) was 19.47%, and for the last 5 years (2020-2024) was 29.55%.
What are Takeda Pharmaceutical Company’s revenue streams?
Takeda Pharmaceutical Company's revenue streams in r 24 are Adcetris, Adderall XR, Advate, Adynovate/Adynovi, Albumin, Alofisel, Alunbrig, Azilva-F, Dexilant, Elaprase, Entyvio, Feiba, Fosrenol, Gastroenterology, Gattex/Revestive, Iclusig, Immunoglobulin, Intuniv, Leuplin/Enantone, Neuroscience, Ninlaro, Oncology, Other Gastroenterology, Other PDT Immunology, Other Product, Other Product, Other, Other Rare Hematology, PDT Immunology, Pantoloc/Controloc, Rare Diseases, Rare Hematology, Recombinate, Replagal, Takhzyro, Trintellix, Velcade, Vpriv, and Vyvanse/Elvanse. Adcetris generated $109.42B in revenue, accounting 1.28% of the company's total revenue, up 30.37% year-over-year. Adderall XR generated $41.76B in revenue, accounting 0.49% of the company's total revenue, up 71.80% year-over-year. Advate generated $122.91B in revenue, accounting 1.44% of the company's total revenue, up 4.00% year-over-year. Adynovate/Adynovi generated $66.31B in revenue, accounting 0.78% of the company's total revenue, down -0.37% year-over-year. Albumin generated $133.99B in revenue, accounting 1.57% of the company's total revenue, up 10.33% year-over-year. Alofisel generated $3.51B in revenue, accounting 0.04% of the company's total revenue, up 28.92% year-over-year. Alunbrig generated $28.52B in revenue, accounting 0.33% of the company's total revenue, up 38.76% year-over-year. Azilva-F generated $33.64B in revenue, accounting 0.39% of the company's total revenue, down -53.86% year-over-year. Dexilant generated $45.28B in revenue, accounting 0.53% of the company's total revenue, down -34.73% year-over-year. Elaprase generated $91.56B in revenue, accounting 1.07% of the company's total revenue, up 7.31% year-over-year. Entyvio generated $800.92B in revenue, accounting 9.38% of the company's total revenue, up 13.97% year-over-year. Feiba generated $40.54B in revenue, accounting 0.48% of the company's total revenue, down -1.76% year-over-year. Fosrenol generated $13.53B in revenue, accounting 0.16% of the company's total revenue Gastroenterology generated $1.22T in revenue, accounting 14.25% of the company's total revenue, up 11.12% year-over-year. Gattex/Revestive generated $119.25B in revenue, accounting 1.40% of the company's total revenue, up 28.12% year-over-year. Iclusig generated $54.71B in revenue, accounting 0.64% of the company's total revenue, up 15.89% year-over-year. Immunoglobulin generated $644.59B in revenue, accounting 7.55% of the company's total revenue, up 23.43% year-over-year. Intuniv generated $33.56B in revenue, accounting 0.39% of the company's total revenue Leuplin/Enantone generated $107.35B in revenue, accounting 1.26% of the company's total revenue, down -3.56% year-over-year. Neuroscience generated $627.01B in revenue, accounting 7.35% of the company's total revenue, down -1.68% year-over-year. Ninlaro generated $87.36B in revenue, accounting 1.02% of the company's total revenue, down -5.75% year-over-year. Oncology generated $462.36B in revenue, accounting 5.42% of the company's total revenue, up 5.38% year-over-year. Other Gastroenterology generated $82.23B in revenue, accounting 0.96% of the company's total revenue, up 13.59% year-over-year. Other PDT Immunology generated $39.99B in revenue, accounting 0.47% of the company's total revenue, up 14.97% year-over-year. Other Product generated $368.91B in revenue, accounting 4.32% of the company's total revenue, down -18.85% year-over-year. Other Product, Other generated $321.74B in revenue, accounting 3.77% of the company's total revenue, down -11.84% year-over-year. Other Rare Hematology generated $47.3B in revenue, accounting 0.55% of the company's total revenue, up 2.01% year-over-year. PDT Immunology generated $818.57B in revenue, accounting 9.59% of the company's total revenue, up 20.65% year-over-year. Pantoloc/Controloc generated $46.5B in revenue, accounting 0.54% of the company's total revenue, up 2.15% year-over-year. Rare Diseases generated $770.7B in revenue, accounting 9.03% of the company's total revenue, up 6.53% year-over-year. Rare Hematology generated $305.3B in revenue, accounting 3.58% of the company's total revenue, up 0.19% year-over-year. Recombinate generated $12.05B in revenue, accounting 0.14% of the company's total revenue, down -5.58% year-over-year. Replagal generated $73.55B in revenue, accounting 0.86% of the company's total revenue, up 10.21% year-over-year. Takhzyro generated $178.68B in revenue, accounting 2.09% of the company's total revenue, up 17.71% year-over-year. Trintellix generated $104.8B in revenue, accounting 1.23% of the company's total revenue, up 4.71% year-over-year. Velcade generated $5.54B in revenue, accounting 0.06% of the company's total revenue, down -80.05% year-over-year. Vpriv generated $51.3B in revenue, accounting 0.60% of the company's total revenue, up 6.04% year-over-year. Vyvanse/Elvanse generated $423.22B in revenue, accounting 4.96% of the company's total revenue, down -7.85% year-over-year.
What is Takeda Pharmaceutical Company’s main source of revenue?
For the fiscal year ending Mar 24, the largest source of revenue of Takeda Pharmaceutical Company was Gastroenterology. This segment made a revenue of $1.22T, representing 14.25% of the company's total revenue.